BOSTON, MA — Margaret Calloway's oncologist gave her two choices in the spring of 2024. The first was the same platinum-based chemotherapy regimen that had been the standard of care for nearly two decades. The second was a combination of two immunotherapy drugs that her oncologist described, carefully, as "the new standard." Margaret, a 71-year-old retired schoolteacher whose husband had brought asbestos dust home from a shipyard in Quincy for thirty years, asked the question that every patient in that situation asks: "Which one actually works better?"
The answer, it turns out, is not simple. But it is increasingly clear. The shift from chemotherapy to dual immunotherapy as the preferred first-line treatment for unresectable pleural mesothelioma is one of the most significant changes in this disease's treatment history, and in 2026, its implications are still unfolding for the roughly 3,000 Americans diagnosed each year. Understanding what the evidence actually shows, who benefits most, and what comes next is not just an academic exercise. For patients like Margaret, it's the difference between months and years.
What the CheckMate 743 Trial Actually Proved
The CheckMate 743 trial established that nivolumab plus ipilimumab, a combination of two immune checkpoint inhibitors, produced meaningfully longer survival than standard chemotherapy in patients with unresectable pleural mesothelioma, with the benefit concentrated in patients whose tumors had non-epithelioid histology. Published in the New England Journal of Medicine in 2021, the trial enrolled 605 patients across 103 sites in 21 countries and compared the dual immunotherapy regimen directly against cisplatin or carboplatin plus pemetrexed, the chemotherapy combination that had been the backbone of mesothelioma treatment since the FDA approved pemetrexed in 2004.
According to the NEJM publication, the median overall survival for patients receiving nivolumab plus ipilimumab was 18.1 months, compared with 14.1 months for chemotherapy, a difference of four months that translated into a statistically significant hazard ratio of 0.74. But the aggregate numbers obscure a more dramatic story in the subgroup data. Among patients with non-epithelioid mesothelioma, a category that includes sarcomatoid and biphasic subtypes and historically carries the worst prognosis, the median overall survival with dual immunotherapy was 18.1 months versus just 8.8 months with chemotherapy. That is more than double the survival time in a population that had previously had almost no effective options.
The FDA approved nivolumab plus ipilimumab for unresectable pleural mesothelioma in October 2020, making it the first new first-line approval in this disease in sixteen years, according to FDA drug approval records. The approval came under the FDA's Breakthrough Therapy designation, reflecting the agency's assessment that the data represented a substantial improvement over available therapy.
What the trial did not show, and what remains a source of ongoing clinical debate, is a clear survival advantage for patients with epithelioid histology, the most common subtype. In that group, the survival curves for immunotherapy and chemotherapy were closely matched, and some analyses suggest chemotherapy may perform comparably or even slightly better in certain epithelioid patients. This is not a minor footnote. Epithelioid mesothelioma accounts for roughly 70 percent of all cases, meaning the majority of patients face a genuine decision about which approach is right for them rather than a clear directive.
Why This Matters More Than Any Single Survival Number
What I hear from patients going through this is that the survival statistics, as important as they are, don't capture the full picture of what treatment choice means. The CheckMate 743 results matter not just because of the months they add, but because of what they represent: the first time in this disease's modern treatment history that the immune system itself has been successfully recruited as a therapeutic ally.
Chemotherapy with cisplatin and pemetrexed works by directly attacking dividing cells, which means it attacks cancer cells but also damages healthy tissue, producing the fatigue, nausea, and neuropathy that patients know well. Immune checkpoint inhibitors work differently. Nivolumab blocks the PD-1 pathway, preventing tumors from essentially hiding from the immune system. Ipilimumab blocks CTLA-4, a separate checkpoint that normally puts the brakes on immune activation. Together, according to research published in the Journal of Thoracic Oncology, they can produce durable immune responses that in some patients persist long after treatment ends.
Durability is the word oncologists keep returning to. In the CheckMate 743 data, a subset of patients receiving dual immunotherapy achieved what researchers describe as long-term survival, defined as surviving beyond 24 months. According to the NEJM publication, 41 percent of patients in the immunotherapy arm were alive at two years, compared with 27 percent in the chemotherapy arm. For a disease where median survival has historically been measured in months, the possibility of two-year and even three-year survival represents a genuine shift in what patients and families can hope for.
For veterans, who represent a disproportionate share of mesothelioma patients due to widespread asbestos use in military construction and shipbuilding, this shift in treatment options intersects with a separate set of questions about access and coverage. Veterans navigating the VA system can find guidance on treatment access and VA benefits eligibility through resources specifically designed for their situation. Understanding mesothelioma treatment options available to veterans is a critical first step before any treatment conversation with an oncologist.
"The most important step you can take right now is getting to a mesothelioma specialist, not a general oncologist, before committing to any first-line treatment," said Yvette Abrego, patient advocate at Mesothelioma-Lung-Cancer.org. "The histology of your tumor changes the entire conversation, and that conversation needs to happen with someone who has seen this disease before."
Who Benefits Most, and Who Should Think Carefully
Imagine two patients sitting in the same oncology waiting room, both diagnosed with unresectable pleural mesothelioma in the same month. One has sarcomatoid histology. The other has epithelioid. Under the old treatment paradigm, both would likely have received the same chemotherapy regimen. Under the current evidence, their optimal treatment paths may diverge significantly.
For the patient with sarcomatoid or biphasic mesothelioma, the CheckMate 743 data makes a compelling case for dual immunotherapy as the first-line choice. The magnitude of benefit in non-epithelioid subtypes, more than nine additional months of median survival, is large enough that most mesothelioma specialists consider it practice-defining. Moffitt Cancer Center, one of the leading mesothelioma treatment programs in the country, notes that histologic subtype is among the most important factors in treatment planning for pleural mesothelioma.
For the patient with epithelioid mesothelioma, the decision is more nuanced. Some oncologists still prefer to start with chemotherapy, particularly for patients who may be candidates for surgery later, since the interaction between prior immunotherapy and surgical outcomes is not yet fully characterized. A systematic review and meta-analysis published in the journal Cancer examined surgical approaches including pleurectomy/decortication and extrapleural pneumonectomy, and the integration of systemic therapy with surgical planning remains an active area of investigation. The research published in PMC examining pleurectomy/decortication versus extrapleural pneumonectomy found that surgical approach itself significantly affects outcomes, reinforcing the importance of multidisciplinary evaluation.
PD-L1 expression, a biomarker that indicates how much a tumor is expressing the protein that checkpoint inhibitors target, was not predictive of benefit in CheckMate 743 in the way it is in lung cancer. According to the NEJM data, patients with low or undetectable PD-L1 expression still derived benefit from dual immunotherapy, which means PD-L1 testing alone cannot be used to exclude patients from consideration. This is a meaningful distinction from other tumor types where PD-L1 status drives treatment selection more directly.
Age and performance status also factor into the calculus. Dual immunotherapy carries its own toxicity profile, including immune-related adverse events that can affect the lungs, liver, colon, and endocrine system. According to the CheckMate 743 publication, grade 3 or 4 adverse events occurred in 33 percent of patients receiving immunotherapy versus 36 percent receiving chemotherapy, suggesting that the toxicity burden is broadly comparable, though the nature of the side effects differs substantially. Patients with autoimmune conditions or those on immunosuppressive medications may not be good candidates for checkpoint inhibitor therapy.
For patients exploring the full landscape of treatment options, including clinical trials that may offer access to emerging combinations, the NCI clinical trials search database allows patients to search by diagnosis, location, and treatment type. Finding a mesothelioma specialist near you can also help identify centers actively enrolling in trials.
!Medical trial documents with pen and glasses on desk, showing survival data comparison
What Comes After First-Line Treatment Fails
For many patients, the question of what to do when first-line therapy stops working is just as pressing as the initial treatment decision. This is where the evidence base becomes thinner and the options more variable.
For patients who received chemotherapy first and progress, switching to nivolumab plus ipilimumab or to single-agent nivolumab is a reasonable consideration, though the data supporting second-line immunotherapy in mesothelioma is less robust than the first-line CheckMate 743 evidence. Conversely, patients who received dual immunotherapy first and progress may be candidates for chemotherapy, and some oncologists report meaningful disease control with pemetrexed-based regimens in the second-line setting.
Tumor Treating Fields, a technology that uses alternating electric fields to disrupt cancer cell division, has also emerged as a potential addition to chemotherapy in mesothelioma. The STELLAR trial, whose results were published in a peer-reviewed PMC study, evaluated TTFields combined with chemotherapy and found a median overall survival of 18.2 months, which compared favorably to historical chemotherapy benchmarks. The FDA granted TTFields a Humanitarian Device Exemption for pleural mesothelioma in 2019, and some centers are now incorporating it into multimodal treatment plans.
Bevacizumab, an anti-angiogenic agent that blocks the blood vessel growth tumors depend on, has also been studied in combination with chemotherapy. Research published in a PMC review of bevacizumab in pleural mesothelioma found that adding bevacizumab to cisplatin and pemetrexed produced a modest but statistically significant improvement in overall survival in the MAPS trial, with median survival of 18.8 months versus 16.1 months for chemotherapy alone. Some European centers incorporate bevacizumab into first-line chemotherapy regimens, though it is not standard practice in the United States.
Gene therapy approaches, while still largely experimental, represent a longer-term horizon. A review of gene therapy strategies for mesothelioma published in PMC described several mechanisms under investigation, including suicide gene therapy, immune-stimulating gene constructs, and tumor suppressor restoration. None of these approaches has yet reached late-phase clinical trials in mesothelioma, but the field is advancing.
For patients and families navigating second-line and beyond, understanding the full spectrum of immunotherapy options can help frame conversations with oncologists about what trials or approved therapies might apply.
What Should Patients and Families Do Next
A few years ago, a family I worked with spent three months at a community hospital getting chemotherapy before anyone told them that a major cancer center two states away had a mesothelioma program with access to clinical trials. By the time they transferred care, options had narrowed. That story is not unusual, and it's one of the reasons I believe so strongly that the first decision, where to get treated, is often the most consequential one.
Many patients and families I've worked with underestimate how much the treating institution matters in mesothelioma. This is a rare cancer, and the gap between a general oncologist who sees one or two cases a year and a specialist at a dedicated mesothelioma program who sees dozens is not small. The National Cancer Institute designates comprehensive cancer centers based on their research and clinical capacity, and mesothelioma patients who can access these centers typically have exposure to more treatment options, more clinical trials, and more experienced multidisciplinary teams.
The most important step you can take right now, if you or someone you love has been diagnosed, is to request a second opinion at a mesothelioma-specialized center before starting any treatment. Chemotherapy can be started at any time. A second opinion costs nothing but time, and in mesothelioma, where histology and staging determine so much of the treatment roadmap, getting the diagnosis right is foundational.
Beyond the clinical decisions, there is a financial reality that cannot be ignored. Dual immunotherapy with nivolumab plus ipilimumab carries significant costs, and patients who were exposed to asbestos through their work or a family member's work may have legal options that can help cover treatment expenses. Asbestos trust funds, established by bankrupt asbestos manufacturers, hold more than $30 billion in reserved compensation for diagnosed patients, according to legal industry data. Understanding what compensation options may be available, or consulting the trust fund directory to identify funds tied to specific employers or products, can be an important parallel track to treatment planning.
For veterans specifically, the VA's Caregiver Support Program and the VA's cancer care benefits can help offset treatment costs, but navigating those systems requires knowing what to ask for. Resources on VA benefits for mesothelioma can help families understand what they're entitled to before the first appointment.
The landscape of mesothelioma treatment has changed more in the past five years than in the previous fifteen. Dual immunotherapy has given oncologists a new first-line tool with real survival benefits in specific populations. TTFields has added another modality. Surgical techniques continue to be refined. And a generation of clinical trials is testing combinations that may further extend survival for patients diagnosed today.
For Margaret Calloway, the choice ultimately came down to histology. Her tumor was biphasic. Her oncologist recommended nivolumab plus ipilimumab. At her six-month scan, her disease was stable. She is, as she puts it, still here.
That is what these treatment advances mean in practice. Not statistics on a page, but people who are still here.
How Does Dual Immunotherapy Compare to Chemotherapy for Quality of Life?
Survival data tells part of the story. Quality of life during treatment tells another. For patients weighing nivolumab plus ipilimumab against cisplatin and pemetrexed, the toxicity profiles matter as much as the efficacy numbers.
Chemotherapy's side effects in mesothelioma are well-characterized: fatigue, nausea, bone marrow suppression, and peripheral neuropathy are common. Pemetrexed requires supplementation with folic acid and vitamin B12 to reduce toxicity, and patients typically receive treatment in three-week cycles that can be physically demanding. According to FDA approval documentation for pemetrexed, the drug was approved specifically for malignant pleural mesothelioma in combination with cisplatin based on a trial showing improved survival and symptom control.
Immunotherapy's side effects are different in character. Immune-related adverse events can affect virtually any organ system, and while most are manageable with corticosteroids, some can be severe. The CheckMate 743 data showed that serious adverse events occurred in roughly comparable proportions across both arms, but the distribution was different. Patients on immunotherapy were more likely to experience endocrine disruption, rash, and colitis, while chemotherapy patients more often experienced hematologic toxicity and nausea.
Patient-reported outcomes from CheckMate 743, according to the NEJM publication, showed that both treatment arms had similar impacts on health-related quality of life overall, with no statistically significant difference in time to deterioration on key symptom measures. This suggests that for most patients, the immunotherapy regimen does not impose a meaningfully worse quality-of-life burden than chemotherapy, while offering superior survival in specific histologic subgroups.
Understanding the differences between mesothelioma and other thoracic malignancies, including how treatment approaches diverge, can also help patients contextualize their options. A comparison of mesothelioma versus lung cancer highlights why disease-specific expertise matters so much in treatment planning.
FAQ
This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider for guidance specific to your situation.
